Αρχειοθήκη ιστολογίου

Πέμπτη 7 Φεβρουαρίου 2019

Construct validity and responsiveness of the Colombian version of Skindex‐29

Abstract

Background

In recent years, the need for international objective Patient‐Reported‐Outcomes measures has grown, as international collaboration has increased. As most Quality of Life scales have been developed in English, there is a growing need to adapt them transculturally to obtain equivalence between the original instrument and the adapted scale.

Aim

To assess the construct and convergent/discriminant validity and responsiveness of the Colombian version of Skindex‐29.

Patients and Methods

Validity and responsiveness were tested cross‐sectionally and longitudinally in both, healthy and dermatological patients. Construct validity was tested through a confirmatory factor analysis. The convergent/discriminant validity was assessed by examining the Spearman correlation coefficient. Change sensitivity was tested by means of the standardized response mean. The effect size and the minimum detectable change, were also assessed.

Results

Two‐hundred sixty‐five participants were included. Among these, 21·2% were healthy individuals, and 78·8% patients had either inflammatory or non‐inflammatory skin diseases. Confirmatory factor analysis showed an adequate comparative fit Index and Tucker‐Lewis index adjustment for the root mean square error of approximation. Convergent validity showed moderate correlations between the emotions, functioning and physical function/physical role domains. Discriminant validity showed low correlations between overall domains for both scales. Sensitivity to change at the first and third month showed effect sizes in global Skindex scores of 0·92 and 0·82, respectively.

Conclusions

The Colombian version of Skindex‐29 is a valid and clinically sensitive instrument that can be used for clinical practice and also for research to measure the impact of skin diseases in quality‐of‐life in our dermatological population.

This article is protected by copyright. All rights reserved.



http://bit.ly/2RKLwCQ

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου